Last reviewed 2026-04-20 · How we verify

IV Glofitamab

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Cytokine release syndrome
• Anaemia
• Diarrhoea
• Hypomagnesaemia
• Neuropathy peripheral
• Neutropenia
• Thrombocytopenia
• Constipation
• Nausea
• Fatigue
• Liver function test abnormal
• Platelet count decreased

Key clinical trials

• A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma (PHASE1)
• Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) for Previously Untreated Mantle Cell Lymphoma (PHASE1)
• Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy (PHASE2)
• A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Mosunetuzumab or Glofitamab in Combination With CC-220 and/or CC-99282 in Participants With B-Cell Non-Hodgkin Lymphoma (PHASE1)
• An Open-Label Study Comparing Glofitamab and Polatuzumab Vedotin + Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone Versus Pola-R-CHP in Previously Untreated Patients With Large B-Cell Lymphoma (PHASE3)
• CAR-T Followed by Bispecific Antibodies (PHASE2)
• Glofit and Obin in Follicular Lymphoma and Marginal Zone Lymphoma (PHASE2)
• A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS-7) (PHASE1)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.